Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 3/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185653 | 0.80 | CYP3A4 (0.52) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL17049170 | 0.75 | TDP1 (0.42) | ALDH1A1MCL1CYP3A4ERN1CD44 | |
| SCHEMBL16018701 | 0.75 | GRIA1 (0.41) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL30561864 | 0.74 | CYP3A4 (0.55) | ALDH1A1SMN1; SMN2TSHRCYP3A4MAPK1 | |
| SCHEMBL841555 | 0.74 | CYP3A4 (0.55) | ALDH1A1SMN1; SMN2TSHRCYP3A4MAPK1 | |
| SCHEMBL2884919 | 0.74 | GRIA1 (0.56) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL25648747 | 0.73 | GRIA1 (0.40) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL3204262 | 0.73 | TSHR (0.48) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL12215999 | 0.72 | GRIA1 (0.43) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL18128766 | 0.71 | GRIA1 (0.54) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211934-B2 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110160263-A1 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-06-30 | — | — | US | disclosed |
| US-7795295-B2 | Small molecule inhibition of PDZ-domain interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080064733-A1 | Small Molecule Inhibition of Pdz-Domain Interaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064733-A1 | Small Molecule Inhibition of Pdz-Domain Interaction | DVL1, DVL3, PDLIM5 | GRIA1 1577/4885GRIA2 2311/4885GRIA3 1483/4885 |
| US-20110160263-A1 | Small molecule inhibition of PDZ-domain interaction | DVL1, DVL3, PDLIM5 | GRIA1 1555/4885GRIA2 2237/4885GRIA3 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.